{"url_path":"/sec/nvax/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-02-26","source_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001000694-26-000007-index.html","accession_number":"0001000694-26-000007","cik":"0001000694","ticker":"NVAX","issuer_name":"NOVAVAX INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001000694-26-000007-index.html","primary_entity_key":"0001000694","primary_entity_name":"NOVAVAX INC"},"word_count":3948,"has_tables":true,"body_markdown":"Item 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES\n\n(a)The following documents are filed as part of the Annual Report on Form 10-K:\n\n(1)Index to Financial Statements\n\n[Reports of Independent Registered Public Accounting Firm (PCAOB ID:42)](#ib45320eea17c45ce95b2b2a9a4dd7402_166)\n\nF- [2](#ib45320eea17c45ce95b2b2a9a4dd7402_166)\n\n[Consolidated Statements of Operations and Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, 2024, and 2023](#ib45320eea17c45ce95b2b2a9a4dd7402_169)\n\nF- [5](#ib45320eea17c45ce95b2b2a9a4dd7402_169)\n\n[Consolidated Balance Sheets as of December 31, 2025 and 2024](#ib45320eea17c45ce95b2b2a9a4dd7402_172)\n\nF- [6](#ib45320eea17c45ce95b2b2a9a4dd7402_172)\n\n[Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2025, 2024, and 2023](#ib45320eea17c45ce95b2b2a9a4dd7402_175)\n\nF- [7](#ib45320eea17c45ce95b2b2a9a4dd7402_175)\n\n[Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023](#ib45320eea17c45ce95b2b2a9a4dd7402_178)\n\nF- [8](#ib45320eea17c45ce95b2b2a9a4dd7402_178)\n\n[Notes to Consolidated Financial Statements](#ib45320eea17c45ce95b2b2a9a4dd7402_181)\n\nF- [9](#ib45320eea17c45ce95b2b2a9a4dd7402_181)\n\n(2)Financial Statement Schedules\n\nFinancial statement schedules are omitted because they are not applicable, not required under the instructions or all the information required is set forth in the financial statements or notes thereto.\n\n(3)Exhibits\n\nExhibit list\n\nExhibit\nNumberDescription\n\n2.1\n[Asset Purchase Agreement, by and between Novavax CZ a.s., Novo Nordisk Production Czech s.r.o. and Novo Nordisk A/S, dated as of December 3, 2024](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex21.htm)[(Incorporated by reference to Exhibit 2.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770)).](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex21.htm)\n\n3.1\n[Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm)\n\n3.2\n[Certificate of Amendment](https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm)[of](https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm)[the Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.](https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm)[1](https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm)[to the Company’s Current Report on Form 8-K filed on May 9, 2019 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm)\n\n3.3\n[Amended and Restated By-Laws of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000011/novavaxinc-amendedandresta.htm)[26](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000011/novavaxinc-amendedandresta.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000011/novavaxinc-amendedandresta.htm)[4](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000011/novavaxinc-amendedandresta.htm)[(File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000011/novavaxinc-amendedandresta.htm)\n\n3.4\n[Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex3-1.htm)\n\n4.1\n[Specimen stock certificate for shares of common stock of the Company, par value $.01 per share (Incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, filed on December 31, 2019 (File No. 333-235761))](https://www.sec.gov/Archives/edgar/data/0001000694/000110465919077299/tv535518_ex4-1.htm)\n\n4.2\n[Indenture (including form of Notes) with respect to the Company's 5.00% Convertible Senior Notes due 2027, dated as of December 20, 2022, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on December 21, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm)\n\n4.3\n[Indenture](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[with resp](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[ect to the Company](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[’](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[s 4.625% Converti](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[ble Senior Notes due 2031](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[, dated](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[as of](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[August 27, 2025, between Novavax, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed August 27, 2025 (File No. 000- 26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)\n\n89\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)\n\n4.4\n[Form of 4.625% Convertible Senior Notes due 2031 (included as Exhibit A to Exhibit 4.1)](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)[(Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed August 27, 2025 (File No. 000- 26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/tm2524511d1_ex4-1.htm)\n\n4.5\n[Form of Exchange and Subscription Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 2](https://www.sec.gov/Archives/edgar/data/1000694/000110465925081160/tm2524045d1_ex10-1.htm)[1](https://www.sec.gov/Archives/edgar/data/1000694/000110465925081160/tm2524045d1_ex10-1.htm)[, 2025 (File No. 000- 26770)).](https://www.sec.gov/Archives/edgar/data/1000694/000110465925081160/tm2524045d1_ex10-1.htm)\n\n4.6\n\n[Form of Series A Convertible Preferred Stock Certificate of the Company (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000110465920075307/tm2023024d1_ex4-1.htm)\n\n4.7*\n\n[Description of the Company's Securities](nvax-20251231xex47.htm)\n\n10.1††\n[The Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit 10.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 12, 2013 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex10-2.htm)\n\n10.2††\n\n[Form of Non-Statutory Stock Option Award Agreement granted under the Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed on February 27, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415012379/v401319_ex10-4.htm)\n\n10.3††\n\n[Form of Incentive Stock Option Award Agreement granted under the Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed on February 27, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415012379/v401319_ex10-5.htm)\n\n10.4††\n\n[Amended and Restated Novavax, Inc. 2013 Employee Stock Purchase Plan (Incorporated by reference to Appendix](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[B](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[of the Company’s Definitive Proxy Statement filed on](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[April 29, 2024](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[in connection with the Annual Meeting held on June 1](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[3](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[, 202](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[4](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[(File No. 000-26770))](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)\n\n10.5††\n\n[Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[Appendix](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[A](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[of the Company’s Definitive Proxy Statement filed on April 2](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[9](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[, 202](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[4](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[in connection with the Annual Meeting held on](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[June 13, 2024](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)[(File No. 000-26770))](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001000694/000100069424000020/nvax-20240429.htm)\n\n10.6††\n\n[Form of Non-Statutory Stock Option Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-3.htm)\n\n10.7††\n\n[Form of Non-Statutory Stock Option Award Agreement (Non-Employee Director) granted under the Company’s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex109.htm)\n\n10.8††\n\n[Form of Global Non-Statutory Stock Option Award Agreement granted under the Company’s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.10 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex1010.htm)\n\n10.9††\n\n[Form of Incentive Stock Option Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm)\n\n10.10††\n\n[Form of Incentive Stock Option Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed on February 27, 2017 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm)\n\n10.11††\n\n[Form of Incentive Stock Option Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Performance- and Time-Based Vesting) (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on November 16, 2016 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420416134953/v453291_ex10-1.htm)\n\n90\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)\n\n10.12††\n\n[Form of Restricted Stock Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm)\n\n10.13††\n\n[Form of Restricted Stock Unit Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed on March 18, 2019 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm)\n\n10.14††\n\n[Form of Restricted Stock Unit Award Agreement (Non-Employee Director) granted under the Company’s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.11 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex1011.htm)\n\n10.15††\n\n[Form of Global Restricted Stock Unit Award Agreement granted under the Company’s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.12 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex1012.htm)\n\n10.16††\n\n[Form of Stock Appreciation Right Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed on November 7, 2019 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm)\n\n10.17††\n\n[Form of Director Deferred Fee Agreement (Incorporated by reference to Exhibit 10.10 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed on February 29, 2016 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420416084770/v431853_ex10-10.htm)\n\n10.18††\n\n[Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-1.htm)\n\n10.19††\n\n[Form of Non-Statutory Stock Option Agreement under the Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-2.htm)\n\n10.20††\n\n[Form of Restricted Stock Unit Award Agreement under the Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-3.htm)\n\n10.21††\n\n[Employment Agreement between the Company and John C. Jacobs, dated as of January 5, 2023 (Incorporated by reference to Exhibit 10.18 to the Company’s Annual Report on Form 10-K, filed on February 28, 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000005/nvax-20221231xex1018.htm)\n\n10.22††\n\n[Consulting and Advisory Agreement between the Company and John Trizzino, dated May 27, 2025 (Incorporated by reference to Exhibit 10.2 to the Company](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[’](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[s Quarterly Report on Form 10-Q for the quarter ended June](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[30, 2025, filed on August 6, 2025](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[(](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[File No. 000-26770](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx102.htm)\n\n10.23††*\n\n[Amendment to Consulting and Advisory Agreement b](nvax-20251231xex1023.htm)[etween the Company and John Trizzino, dated December 18, 2025](nvax-20251231xex1023.htm)\n\n10.24††\n\n[Employment Agreement between the Company and James P. Kelly dated July 12, 2021 (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex101.htm)\n\n10.25††\n\n[Offer letter to James P. Kelly dated July 12, 2021 (Incorporated by reference to Exhibit 10.2 to the Company’s](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm)[Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm)\n\n10.26††\n\n[Offer letter to Mark Casey dated November 10, 2023](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1032.htm)[(Incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1032.htm)\n\n10.27††\n\n[Employment Agreement between the Company and Mark Casey dated November 10, 2023](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1033.htm)[(Incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1033.htm)\n\n91\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)\n\n10.28††\n\n[Offer Letter to Elaine O’Hara dated February 4, 2023](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1034.htm)[(Incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1034.htm)\n\n10.29††\n\n[Employment Agreement between the Company and Elaine O’Hara dated February 4, 2023](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1035.htm)[(Incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex1035.htm)\n\n10.30††\n\n[Company Amended and Restated Change in Control Severance Benefit Plan (Incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex104.htm)\n\n10.31††\n\n[Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 3.5 in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 8, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331xex35.htm)\n\n10.32††\n\n[Form of Indemnification Agreement entered into between the Company and its directors and officers (Incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed on March 16, 2010 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420410013614/v176992_ex10-19.htm)\n\n10.33+\n\n[Lease Agreement for space at 22 Firstfield Road between ARE-20/22/1300 Firstfield Quince Orchard, LLC and the Company, dated as of November 18, 2011 (Incorporated by reference to Exhibit 10.25 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 14, 2012 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420412014910/v304706_ex10-25.htm)\n\n10.34\n\n[Deed of Lease for space at 21 Firstfield Road between Firstfield Holdco, LLC and the Company, dated as of February 4, 2015 (Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on August 21, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415051329/v418551_ex10-1.htm)\n\n10.35\n[First Amendment to Deed of Lease for space at 21 Firstfield Road between Firstfield Holdco, LLC and the Company, dated as of August 17, 2015 (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on August 21, 2015 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420415051329/v418551_ex10-2.htm)\n\n10.36\n[Second Amendment to Deed of Lease for space at 21 Firstfield Road between BMR-Firstfield LLC (formerly Firstfield Holdco, LLC) and the Company, dated as of March 31, 2017 (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed on May 8, 2017 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000114420417025227/v465353_ex10-2.htm)\n\n10.37^+\n\n[Assignment and Assumption of Lease between the Company and AstraZeneca Pharmaceuticals, LP, dated October 17, 2025 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 22, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/tm2529188d1_ex10-1.htm)\n\n10.38+\n\n[Amended and Restated Supply and License Agreement, dated July 1, 2021, between the Company and Serum Institute of India Private Limited (Incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex104.htm)\n\n10.39^+\n\n[Supply Agreement between the Company, Serum Institute of India Private Limited and Serum Life Sciences Limited, executed as of October 26, 2021 (Incorporated by reference to Exhibit 10.37 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm)\n\n10.40^+\n\n[Contract Development Manufacture Agreement, dated October 21, 2021, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 9, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm)\n\n10.41^\n\n[Amendment No. 1 to the Contract Development Manufacture Agreement, executed as of April 29, 2022, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 9, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex104.htm)\n\n92\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)\n\n10.42^+\n\n[Statement of Work No. 1 to the Contract Development Manufacture Agreement, effective as of April 29, 2022, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 9, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex105.htm)\n\n10.43^+\n\n[Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of February 12, 2021 (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on May 10, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000008/nvax-20210331xex101.htm)\n\n10.44^+\n\n[First Amendment to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Incorporated by reference to Exhibit 10.39 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm)\n\n10.45^+\n\n[Collaboration and Exclusive License Agreement between the Company and Takeda Pharmaceutical Company Limited, dated as of February 24, 2021 (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on May 10, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000008/nvax-20210331xex102.htm)\n\n10.46^+\n\n[Amended](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[Colla](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[boration](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[Agreement](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[with Takeda Pharmaceutical Company Limited](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[dated April 29, 2025](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[(Incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[3](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed on August 6, 2025](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[(](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[File](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[No](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[. 000-26770](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000029/nvax-20250630exx103.htm)\n\n10.47^+\n\n[Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022, between the Company and The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm)\n\n10.48^\n\n[Letter of Amendment to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of September 26, 2022, between the Company and The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex102.htm)\n\n10.49^+\n\n[Advanced Purchase Agreement, effective as of December 31, 2020, between the Company and the Commonwealth of Australia as represented by the Department of Health (Incorporated by reference to Exhibit 10.36 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1036.htm)\n\n10.50^+\n\n[Amendment to Advanced Purchase Agreement between the Company, and the Commonwealth of Australia as represented by the Department of Health, dated as of December 23, 2021 (Incorporated by reference to Exhibit 10.47 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm)\n\n10.51^+\n\n[Amendment No. 2 to Advanced Purchase Agreement, dated as of April 6, 2022, between the Company and the Commonwealth of Australia as Represented by the Department of Health (Incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q filed on August, 8 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm)\n\n10.52^+\n\n[Amendment No. 3 to Advanced Purchase Agreement, dated as of April 5, 2023, between the Company and the Commonwealth of Australia as Represented by the Department of Health (Incorporated by reference to Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q filed on August, 8 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm)\n\n10.53^+\n\n[Amendment No. 4 to Advanced Purchase Agreement, dated as of July 5, 2023, between the Company and the Commonwealth of Australia as Represented by the Department of Health (Incorporated by reference to Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q filed on August, 8 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm)\n\n10.54^+\n\n[A](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[mendment No. 5 to](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[Advance Purchase Agreement,](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[date](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[d as of December 12, 202](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[4](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[, between the Company and the Commonwealth of Australia as Represented by the Department of Health](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[(Incorporated by reference to Exhibit 10.60 to the Company](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[’](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[s Annual Report on Form 10-K filed on February 27, 2025 (File No. 000-](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[267700](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1060.htm)\n\n10.55^+\n[Settlement Agreement and General Release, dated August 8, 2023, between the Company and SK bioscience Co., Ltd. (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed on November, 9 2023 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm)\n\n93\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)\n\n10.56^\n\n[Termination and Settlement Agreement, dated as of February 16, 2024, between the Company and Gavi Alliance](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex10101.htm) [(Incorporated by reference to Exhibit 10.101 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 28, 2024 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm)\n\n10.57^\n\n[Termination and Settlement Agreement, dated November 1, 2024, by and between the Company and The Secretary of State for Health and Social Care, acting as part of the Crown, through the UK Health Security Agency](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1069.htm)[(Incorporated by reference to Exhibit 10.69 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1069.htm)\n\n10.58^\n\n[Letter Amendment to the Termination and Settlement Agreement, dated November 1, 2024, by and between the Company and The Secretary of State for Health and Social Care, acting as part of the Crown, through the UK Health Security Agency](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1070.htm)[(Incorporated by reference to Exhibit 10.70 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex1070.htm)\n\n10.59^+\n\n[Collaboration and License Agreement, dated May 10, 2024, by and between the Company and Sanofi Pasteur Inc. (Incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report for the quarter ended June 30, 2024, filed on August 8, 2024 (File No. 000-26770)).](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000035/nvax-20240630xexhibit104.htm)\n\n10.60^+\n\n[Supply Agreement, dated May 6, 2024, by and between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000035/nvax-20240630xexhibit106.htm)[6](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000035/nvax-20240630xexhibit106.htm)[to the Company’s Quarterly Report for the quarter ended June 30, 2024, filed on August 8, 2024 (File No. 000-26770)).](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000035/nvax-20240630xexhibit106.htm)\n\n10.61\n\n[First Amendment to Collaboration and License Agreement](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[,](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[dated July 28, 2025](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[, by and](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[between the Company and](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[Sanofi Pasteur Inc](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[.](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[(Incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[1](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[to the Company’s Quarterly Report o](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[n Form 10-Q for the quarter ended](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[September](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[30, 2025, filed on](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[N](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[ovember](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[6](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[, 2025 (](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[File](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[No. 000-26770](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)[))](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx101.htm)\n\n10.62^+\n\n[Second Amendment to Collaboration and License Agreement](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[, dated July 28, 202](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[5](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[, by and](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[between the Company and Sanofi Pasteur Inc](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[.](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[(](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[Incorporat](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[ed by reference to Ex](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[hibit 10.2 to the Company](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[’](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[s Quarterly Report on Form 10-Q for the quarter ended Septemb](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[er](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[30, 2025, filed on November](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[6](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[5 (](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[File](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[No. 000-26770](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)[)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000046/nvax-20250930exx102.htm)\n\n10.63*^+\n\n[License Agreement](nvax-20251231xex1063.htm)[, dated January 1](nvax-20251231xex1063.htm)[4](nvax-20251231xex1063.htm)[, 2026](nvax-20251231xex1063.htm)[, by](nvax-20251231xex1063.htm)[and between the Company and Pfizer,](nvax-20251231xex1063.htm)[Inc.](nvax-20251231xex1063.htm)\n\n10.64*+\n\n[Credit, Security and Guaranty Agreement, dated as of February 25, 2026, by and among Novavax, Inc., as borrower, the lenders from time to time party thereto and MidCap Financial Trust, as administrative agent.](nvax-20251231xex1064.htm)\n\n14\n[Code of Conduct (Incorporated by reference to Exhibit 14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm)\n\n19\n[Insider Trading Policy](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex19.htm)[(Incorporated by reference to Exhibit 19 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000004/nvax-20241231xex19.htm)\n\n21*\n[Subsidiaries of the Company](nvax-2025x1231xex21.htm)\n\n23.1*\n[Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm](nvax-20251231xex231.htm)\n\n31.1*\n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act](nvax-20251231xex311.htm)\n\n31.2*\n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act](nvax-20251231xex312.htm)\n\n32.1*\n[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](nvax-20251231xex321.htm)\n\n32.2*\n[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](nvax-20251231xex322.htm)\n\n97\n[Novavax, Inc. Amended and Restated Recoupment Policy](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex97.htm)[(Incorporated by reference to Exhibit 97 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 (File No. 000-26770))](https://www.sec.gov/Archives/edgar/data/1000694/000100069424000007/nvax-20231231xex97.htm)\n\n94\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)\n\n101\nThe following financial information from our Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets as of December 31, 2025 and 2024, (ii) the Consolidated Statements of Operations for the three years in the period ended December 31, 2025, (iii) the Consolidated Statements of Comprehensive Income (Loss) for the three years in the period ended December 31, 2025, (iv) the Consolidated Statements of Changes in Stockholders’ Deficit for the three years in the period ended December 31, 2025, (v) the Consolidated Statements of Cash Flows for the three years in the period ended December 31, 2025, and (vi) the Notes to Consolidated Financial Statements.\n\n104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n*    Filed herewith.\n\n**    Furnished herewith.\n\n††    Indicates management contract or compensatory plan or arrangement.\n\n^    Certain portions of this exhibit (indicated by [***]) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.\n\n+    Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules or similar attachments upon request by the SEC.\n\n95\n\n[Table of Contents](#ib45320eea17c45ce95b2b2a9a4dd7402_7)"}